- Home
- BLIN vs LPTX Comparison
BLIN vs LPTX Comparison
Compare BLIN & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLIN
- LPTX
- Stock Information
- Founded
- BLIN 2000
- LPTX 2011
- Country
- BLIN United States
- LPTX United States
- Employees
- BLIN N/A
- LPTX N/A
- Industry
- BLIN EDP Services
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BLIN Technology
- LPTX Health Care
- Exchange
- BLIN Nasdaq
- LPTX Nasdaq
- Market Cap
- BLIN 17.6M
- LPTX 14.7M
- IPO Year
- BLIN 2007
- LPTX N/A
- Fundamental
- Price
- BLIN $1.42
- LPTX $0.31
- Analyst Decision
- BLIN Strong Buy
- LPTX Hold
- Analyst Count
- BLIN 1
- LPTX 1
- Target Price
- BLIN $4.62
- LPTX N/A
- AVG Volume (30 Days)
- BLIN 66.4K
- LPTX 661.1K
- Earning Date
- BLIN 08-18-2025
- LPTX 08-19-2025
- Dividend Yield
- BLIN N/A
- LPTX N/A
- EPS Growth
- BLIN N/A
- LPTX N/A
- EPS
- BLIN N/A
- LPTX N/A
- Revenue
- BLIN $15,465,000.00
- LPTX N/A
- Revenue This Year
- BLIN $4.08
- LPTX N/A
- Revenue Next Year
- BLIN $12.95
- LPTX N/A
- P/E Ratio
- BLIN N/A
- LPTX N/A
- Revenue Growth
- BLIN 1.30
- LPTX N/A
- 52 Week Low
- BLIN $0.80
- LPTX $0.22
- 52 Week High
- BLIN $2.80
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- BLIN 41.98
- LPTX 43.86
- Support Level
- BLIN $1.42
- LPTX $0.30
- Resistance Level
- BLIN $1.53
- LPTX $0.37
- Average True Range (ATR)
- BLIN 0.09
- LPTX 0.03
- MACD
- BLIN -0.00
- LPTX -0.00
- Stochastic Oscillator
- BLIN 0.00
- LPTX 28.53
About BLIN Bridgeline Digital Inc.
Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.